Artículos de revistas
Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing`s disease
Fecha
2008Registro en:
CLINICAL ENDOCRINOLOGY, v.69, n.1, p.117-122, 2008
0300-0664
10.1111/j.1365-2265.2007.03168.x
Autor
ROMANHOLI, Daniella Jesus Patrick Carminatti
MACHADO, Marcio Carlos
PEREIRA, Camila Canteiro
DANILOVIC, Debora Seguro
PEREIRA, Maria Adelaide Albergaria
CESCATO, Valter Angelo S.
CUNHA NETO, Malebranche Berardo C.
MUSOLINO, Nina Rosa Castro
MENDONCA, Berenice Bilharinho de
SALGADO, Luiz Roberto
Institución
Resumen
In the early postoperative period of Cushing`s disease patients, desmopressin may stimulate ACTH secretion in the remnant corticotrophic tumour, but not in nontumour suppressed cells. Objective The aim of this study is to evaluate the serum cortisol responses to desmopressin after pituitary surgery, establishing an optimal cut-off for absolute increment (Delta) of serum cortisol (F) suitable to predict recurrence risk. Design Retrospective case record study. Patients Fifty-seven Cushing`s disease patients submitted to pituitary surgery and desmopressin stimulation in the early postoperative with a long-term follow-up (20-161 months) were studied. Methods and measurements Serum cortisol levels after desmopressin test (10 mu g IV) 15-30 days after adenomectomy were used to determine Delta F (absolute increment of F: F peak - F baseline). Sensitivity and specificity of Delta F were calculated and a ROC curve was performed to establish an optimal cut-off for Delta F to predict recurrence risk. Results Fifteen patients had immediate postoperative failure (basal F > 165 nmol/l; 6 mu g/dl) and one patient was lost during the follow-up. Forty-one patients achieved initial remission and were followed-up. Five of 11 patients who recurred had Delta F > 193 nmol/l (7 mu g/dl), but none of 30 patients who remained in prolonged remission showed Delta F > 193 nmol/l after postoperative desmopressin stimulation. Conclusions Persistence of cortisol response (Delta F > 193 nmol/l) to desmopressin in the early postoperative period can help to identify Cushing`s disease patients with initial remission who present risk for later recurrence.